Regeneron Pharmaceuticals showcases 36 breakthroughs at AAAAI26

Regeneron Pharmaceuticals is presenting 36 abstracts at the AAAAI26 conference, highlighting their latest advancements in immunology and inflammation research. A significant development includes their first-time Phase 3 presentations for cat and birch allergy treatments. This participation underscores Regeneron’s continued commitment to innovation and progress in the medical field.

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.
  • Reward
  • Comment
  • Repost
  • Share
Comment
0/400
No comments
  • Pin

Trade Crypto Anywhere Anytime
qrCode
Scan to download Gate App
Community
English
  • 简体中文
  • English
  • Tiếng Việt
  • 繁體中文
  • Español
  • Русский
  • Français (Afrique)
  • Português (Portugal)
  • Bahasa Indonesia
  • 日本語
  • بالعربية
  • Українська
  • Português (Brasil)